Homestead Advisers Corp Has $1.50 Million Stock Position in Lantheus Holdings, Inc. $LNTH

Homestead Advisers Corp cut its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 49.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 29,300 shares of the medical equipment provider’s stock after selling 28,900 shares during the quarter. Homestead Advisers Corp’s holdings in Lantheus were worth $1,503,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Hantz Financial Services Inc. lifted its position in Lantheus by 412.5% during the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 396 shares during the last quarter. Elevation Point Wealth Partners LLC bought a new position in shares of Lantheus in the second quarter worth about $26,000. First Horizon Corp bought a new position in shares of Lantheus in the third quarter worth about $26,000. Osterweis Capital Management Inc. acquired a new position in shares of Lantheus during the 2nd quarter worth about $36,000. Finally, Pilgrim Partners Asia Pte Ltd bought a new stake in Lantheus during the 3rd quarter valued at approximately $59,000. Institutional investors own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on LNTH. Weiss Ratings raised Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. The Goldman Sachs Group set a $77.00 price objective on shares of Lantheus and gave the stock a “neutral” rating in a research note on Wednesday, October 8th. Truist Financial boosted their target price on shares of Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Finally, Mizuho increased their price target on shares of Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Five investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $78.00.

Lantheus Stock Performance

LNTH opened at $65.93 on Thursday. The stock’s 50 day simple moving average is $65.35 and its 200-day simple moving average is $59.74. The company has a current ratio of 2.67, a quick ratio of 2.49 and a debt-to-equity ratio of 0.51. The stock has a market cap of $4.37 billion, a PE ratio of 27.70 and a beta of -0.08. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $111.29.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, November 6th. The medical equipment provider reported $1.27 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.27. The firm had revenue of $384.01 million for the quarter, compared to the consensus estimate of $363.42 million. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. The business’s revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.70 earnings per share. Sell-side analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.